2026-10-19T01:56:22Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/113702026-10-18T21:13:15Zopenairedrivercom_ebyu_10000col_ebyu_10001The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life DataGürbüz, YunusKocagül-çelikbaş, AyselÖztoprak, NefiseAygen, BilgehanBatırel, AyşeHabiloğlu, Arif DoğanAktuğ-Demir, NazlımÇeken, SabahatDemirtürk, NeşeCeylan, Mehmet ReşatÜçer, ŞengülKarakeçili, FarukAlkan, Sevilİnce, NevinAkça, AnılGünay, VeliMustanoğlu-özatağ, DuruÇınar, GüleKınıklı, SamiYıldız, OrhanŞarlak-Konya, PetekSümer, ŞuaYekenkurul, DilekÇelik, MehmetBinay, Umut DevrimAşık-Otman, Zahidechronic hepatitis CCOVID-19glecaprevirmulticenter studypibrentasvirObjective: This study aimed to demonstrate the real-life efficacy and safety of glecaprevir / pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients. Materials and Methods: The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-naïve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment Results: Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events. Conclusion: Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics. © 2024, DOC Design and Informatics Co. Ltd.. All rights reserved.DOC Design and Informatics Co. Ltd.2024Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/11370https://doi.org/10.36519/idcm.2024.3442667-646XenInfectious Diseases and Clinical Microbiologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11370